Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Common Equity (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Common Equity for 4 consecutive years, with $29.6 million as the latest value for Q3 2025.

  • Quarterly Common Equity rose 3.8% to $29.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $29.6 million through Sep 2025, up 3.8% year-over-year, with the annual reading at $29.6 million for FY2025, 3.8% up from the prior year.
  • Common Equity hit $29.6 million in Q3 2025 for Jin Medical International, up from $28.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $29.6 million in Q3 2025 to a low of $15.2 million in Q3 2022.
  • Historically, Common Equity has averaged $24.4 million across 4 years, with a median of $26.3 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 57.39% in 2023 and later rose 3.8% in 2025.
  • Year by year, Common Equity stood at $15.2 million in 2022, then soared by 57.39% to $24.0 million in 2023, then increased by 19.07% to $28.6 million in 2024, then increased by 3.8% to $29.6 million in 2025.
  • Business Quant data shows Common Equity for ZJYL at $29.6 million in Q3 2025, $28.6 million in Q3 2024, and $24.0 million in Q3 2023.